Lev Pharmaceuticals to Present at the Jefferies & Co. 2nd Annual Healthcare Conference

NEW YORK--(Business Wire)--
Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP)
announced today that Joshua Schein, Ph.D., chief executive officer of
Lev will present at the Jefferies & Co. 2nd Annual Healthcare
Conference, being held June 24-26 in New York City, NY. Dr. Schein
will present a corporate progress report, including an update on the
Company's lead product candidate, Cinryze(TM) (C1 inhibitor (human)).
The Lev presentation is scheduled to begin at 1:30 p.m. Eastern
Standard Time on Thursday, June 26th.

The Lev presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the Company's website at
www.levpharma.com. The 15-minute presentation will also be available
on the Lev website in replay format for a limited time following the
conference.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and
commercializing therapeutic products for the treatment of inflammatory
diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor
(human)), is being developed as a replacement therapy for hereditary
angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze(TM)
has been granted orphan drug status for the acute and prophylactic
treatment of HAE, potentially securing, upon approval, market
exclusivity for seven years. Additionally, Lev is in the process of
prioritizing its C1 inhibitor development platform for the treatment
of selective other diseases and disorders in which inflammation is
known or believed to play an underlying role.

For more information about Lev, C1 inhibitor, or HAE, please
contact Lev directly at 212-682-3096, or visit Lev's website at
www.levpharma.com.

Forward Looking Statements

This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our plans and objectives of management are forward-looking
statements. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make. Various important factors could cause actual
results or events to differ materially from the forward-looking
statements that we make, including risks related to new information
arising out of clinical trial results, the risk that the safety and/or
efficacy results of existing clinical trials for Cinryze(TM) will not
support approval for a biologics license, the risk that FDA may
require us to conduct additional clinical trials for Cinryze(TM), the
risk that FDA may interpret data differently than we do or require
more data or a more rigorous analysis of data than expected, the risk
that FDA will not approve a product for which a biologics license has
been applied, our heavy dependence on the success of Cinryze(TM), our
dependence on our suppliers, our dependence on third parties to
manufacture Cinryze(TM), obtaining regulatory approval to market
Cinryze(TM), market acceptance of Cinryze(TM), maintaining the orphan
drug status associated with Cinryze(TM), the risks associated with
dependence upon key personnel, and our ability to obtain additional
funding to support our business activities. These and other risks are
described in greater detail in the "Risk Factors that May Affect
Results" section of our filings with the SEC. Our forward-looking
statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we
may make. We do not assume any obligation to update any
forward-looking statements.

Investors:
Lev Pharmaceuticals, Inc.
Jason Tuthill, 212-850-9130
jtuthill@levpharma.com
or
Media:
WeissComm Partners
Katherine Stueland, 312-208-0320
kstueland@wcpglobal.com

Copyright Business Wire 2008